Safe Medications for Migraine During Pregnancy

Acute Treatment Options

• The American College of Obstetricians and Gynecologists recommends paracetamol (acetaminophen) as the first-line medication for acute treatment of migraine during pregnancy, with a recommended dose of 1000 mg 1
• NSAIDs such as ibuprofen can be used as a second-line option only during the second trimester, but should be avoided in the first and third trimesters due to specific risks 1
• Sumatriptan may be used sporadically under strict specialist supervision when other treatments fail, with most safety data supporting sumatriptan specifically among the triptans 1
• Metoclopramide can be used for nausea associated with migraine in pregnancy, particularly during the second and third trimesters 1

Medications to Avoid During Pregnancy

• Ergotamine derivatives and dihydroergotamine are contraindicated during pregnancy due to potential risks to the fetus 1
• Topiramate, candesartan, and sodium valproate are contraindicated due to adverse effects on the fetus 1, 2
• CGRP antagonists (gepants) and ergot alkaloids have insufficient safety data in pregnancy and should be avoided 1
• Opioids and butalbital-containing medications should be limited due to risks of dependency and medication-overuse headache 1

Preventive Treatment Options

• Preventive migraine medications should be avoided during pregnancy unless absolutely necessary for frequent and disabling attacks 1
• If prevention is required, propranolol has the best safety profile and is the first choice for preventive therapy 1
• Amitriptyline can be considered if propranolol is contraindicated 1

Non-Pharmacological Approaches

• Before initiating any pharmacological treatment, non-pharmacological approaches should be tried first 1
• Effective non-pharmacological strategies include staying well hydrated and maintaining regular meals 1
• Securing sufficient and consistent sleep patterns 1
• Engaging in appropriate physical activity 1
• Identifying and avoiding migraine triggers 1

Special Considerations

• Regular monitoring is essential when medications are used during pregnancy, especially for preventive treatments 1
• A new headache in a pregnant woman with hypertension should be considered part of preeclampsia until proven otherwise 1
• Medication overuse headache can occur with frequent use of acute medications (≥15 days/month with NSAIDs; ≥10 days/month with triptans) 1
• Multidisciplinary communication among relevant experienced clinicians should occur throughout pregnancy, peridelivery, and in the postpartum period 2

Postpartum Period

• Paracetamol remains the preferred acute medication during breastfeeding 1
• Ibuprofen and sumatriptan are considered safe during breastfeeding 1
• NSAIDs such as ibuprofen are recommended as first-line treatment for postpartum pain after vaginal delivery 3
• If preventive medication is required postpartum, propranolol is recommended as it has the best safety profile 1, 3

Propranolol Dosing for Migraine Prevention While Breastfeeding

Introduction to Propranolol

• The American Academy of Neurology recommends propranolol as the first-choice medication for migraine prevention in breastfeeding women, at a dose of 80-160 mg orally once or twice daily in long-acting formulations, due to its superior safety profile and minimal infant exposure through breast milk 4, 5, 6

Why Propranolol is Preferred During Breastfeeding

• Propranolol is specifically identified as the first-line preventive agent for the postpartum period because it has superior safety data compared to other preventive medications, as recommended by the American College of Obstetricians and Gynecologists 4, 5, 6
• This low transfer into breast milk makes propranolol safer than alternatives like topiramate or sodium valproate, according to the American Academy of Neurology 4, 5, 6

Specific Dosing Recommendations

• The American Headache Society recommends starting with 80 mg daily in long-acting formulations, which can be given once or twice daily depending on the specific formulation used 4, 5, 6
• The therapeutic range is 80-160 mg per day, with evidence supporting efficacy up to 240 mg daily in the general migraine population, as stated by the American Academy of Neurology 7, 8, 9, 10

Clinical Decision Algorithm

• The American College of Physicians recommends confirming the indication for preventive therapy: ≥2 attacks per month producing disability lasting ≥3 days per month, or contraindication/failure of acute treatments 7, 8, 11
• The American Heart Association suggests screening for contraindications to propranolol: asthma, cardiac failure, Raynaud disease, atrioventricular block, or depression 4, 5, 6

Important Caveats

• The American Academy of Neurology advises avoiding abrupt discontinuation if treatment needs to be stopped, though propranolol can be safely stopped without gradual weaning in most cases 12
• If propranolol is contraindicated, the American College of Obstetricians and Gynecologists recommends amitriptyline as the second-line option during breastfeeding, though it has less favorable safety data than propranolol in this population 4, 5, 6
• The American Headache Society notes that propranolol is more effective for pure migraine, while amitriptyline may be superior for mixed migraine and tension-type headache patterns 7, 8, 9

Monitoring During Treatment

• The British Journal of Dermatology suggests that blood pressure and heart rate do not require routine monitoring between appointments if the patient is well and on a stable dose 12
• The American Academy of Neurology recommends follow-up intervals of 2-3 months for patients on stable treatment without complications 12

Safety of Medications in Pregnancy

Propranolol Safety Profile

• The American College of Cardiology, American Heart Association, and Heart Rhythm Society guidelines list propranolol with a Class IIa recommendation (Level of Evidence C-LD) for ongoing management in pregnant patients, noting it has a longer record of safety compared to other beta-blockers, with a primary concern of intrauterine growth retardation (IUGR), particularly with first trimester exposure and longer duration of treatment 13, 14
• Propranolol is considered a safe first-line agent for chronic prophylaxis during pregnancy, though ideally avoided in the first trimester, with the lowest effective dose (typically 80-160 mg daily for migraine prophylaxis) and titration according to clinical response 13, 14

Critical Pitfalls to Avoid

• Atenolol should be completely avoided due to its potential to cause more pronounced IUGR than propranolol 13
• All medications should be avoided in the first trimester when possible, as this is when the risk of congenital malformations is greatest 13, 14

Migraine Preventive Medication Use in Pregnancy – Evidence‑Based Guidance

Risk–Benefit Assessment

• Clinicians should initiate preventive therapy only when the overall risk–benefit balance clearly favors treatment, because most migraine preventive agents carry fetal safety concerns. 15

First‑Line Preventive Option

• Propranolol (80–160 mg daily) is recommended as the first‑line preventive medication for pregnant patients who require therapy, owing to its comparatively favorable safety profile; however, first‑trimester exposure may be associated with intra‑uterine growth restriction, especially with prolonged use. 15

Second‑Line Preventive Option

• Amitriptyline may be used only when propranolol is contraindicated (e.g., asthma, cardiac failure, Raynaud phenomenon, AV block, or depression). The 2025 American College of Physicians (ACP) guidelines list amitriptyline among four first‑line agents for migraine prevention in non‑pregnant adults, explicitly excluding its use in pregnancy. Consequently, its use in pregnancy should be limited to the lowest effective dose with close monitoring. [16][17]

Medications to Avoid in Pregnancy

Combination Therapy Warning

• The 2025 ACP guidelines found that combining topiramate with amitriptyline provides no additional benefit over monotherapy and is linked to higher adverse‑event rates in the general population; therefore, such combination should be avoided in pregnant patients. 18

Multidisciplinary Management

• Ongoing communication among obstetricians, neurologists, and other relevant clinicians throughout pregnancy, delivery, and the postpartum period is essential to optimize maternal and fetal outcomes. 15